Digest Network Come funziona
Network
/
Società
No
Non verificato

Novartis Pharma AG

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

83 comunicati stampa

Guarda tutti i comunicati
06/03/2026
Farmaceutica
Annunci Economici
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
27/02/2026
Farmaceutica
Annunci Economici
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
27/02/2026
Farmaceutica
Annunci Economici
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmaceutica
Annunci Economici
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
24/02/2026
Farmaceutica
Annunci Economici
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
22/02/2026
Farmaceutica
Annunci Economici
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
17/02/2026
Farmaceutica
Annunci Economici
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
12/02/2026
Farmaceutica
Annunci Economici
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
06/02/2026
Farmaceutica
Annunci Economici
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
03/02/2026
Farmaceutica
Management/Organizzazione Aziendale
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0